Derrick Robertson

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Amit Bar‐Or, Jonathan Calkwood, Cathy Chognot et al. · Neurology · 2020 · 332 citations · Full text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE

Sharon McCarthy, Derrick Robertson, J.J Turner et al. · The Lancet · 1977 · 199 citations

Low-dose Heparin, Thrombosis, Venous Thrombosis +12

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 177 citations · Full text

Neurological Disorder, Phase 2B, Clinical Trials +7